Victoza Approved for Treatment of Type 2 Diabetes in China

The Chinese State Food and Drug Administration (SFDA) has approved Victoza for the treatment of type 2 diabetes.
Diabetes is a rapidly growing disease in China, and Victoza offers a unique treatment option by effectively reducing HbA1c and weight with a low risk of hypoglycemia in people with type 2 diabetes inadequately controlled by oral anti-diabetic agents… Read more

Lilly to Open Diabetes Research Center in Shanghai, China

Eli Lilly has announced plans to open a diabetes research center in Shanghai, China. The center, planned to open in the second half of 2011, will focus on discovering new medicines to treat diabetes.
According to a recent article in The New England Journal of Medicine, an estimated 92 million people in China – almost 10 percent of the adult population – have diabetes… Read more

Diabetes At Epidemic Proportions in China

According to a new study published in the The New England Journal of Medicine, 92.4 million Chinese adults age 20 or older (9.7 percent of the population) have diabetes and 148.2 million more (15.5 percent) have prediabetes. Researchers from Tulane University administered an oral glucose tolerance test to 46,239 adults aged 20 or older from 14 provinces… Read more

Subscribe to our Newsletter

Hide me